Literature DB >> 9687392

In vitro activities of oral beta-lactams at concentrations achieved in humans against penicillin-susceptible and -resistant pneumococci and potential to select resistance.

C E Thorburn1, S J Knott, D I Edwards.   

Abstract

The beta-lactam susceptibilities of 65 strains of Streptococcus pneumoniae for which penicillin MICs covered a broad range were assessed. The order of potency was amoxicillin (AMX) = amoxicillin-clavulanate (AMC) > penicillin G > cefpodoxime (CPO) > cefuroxime (CXM) > cefprozil > cefaclor > loracarbef > cefixime. No decrease in susceptibility was seen following repeated subculture of two penicillin-susceptible strains of S. pneumoniae in AMX, AMC, cefaclor, or loracarbef, whereas repeated exposure to CPO and CXM resulted in 4- to 32-fold decreases in susceptibility for both strains. When one of these strains was exposed to concentrations of CPO, CXM, AMX, and AMC achieved in the serum of humans following the administration of an oral dose, all agents were rapidly bactericidal, with no decrease in susceptibility up to 72 h. This was consistent with antibiotic concentrations exceeding the MICs for 100% of the dosing interval. For a penicillin-resistant strain, MICs were exceeded for 29% of the 12-h dosing interval for 500 mg of AMX, 42% of the interval for AMC with 875 mg of AMX and 125 mg of clavulanate (875/125 mg of AMC) 21% of the interval for 500 mg of CXM, and 0% of the interval for 200 mg of CPO. Consequently, only 875/125 mg of AMC produced a sustained bactericidal effect. A four- to eightfold reduction in susceptibility to CPO and CXM and cross-resistance with cefotaxime, but not penicillin or AMC, were selected following exposure to simulated serum CPO and CXM concentrations. In addition, AMX and AMC were the only agents which consistently produced a >99% reduction in bacterial numbers in time-kill studies using concentrations of antibiotic achieved in middle ear fluid for all three strains of penicillin-resistant S. pneumoniae tested.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9687392      PMCID: PMC105718     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin.

Authors:  E Pérez-Trallero; J M Garcia-Arenzana; J A Jimenez; A Peris
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-12       Impact factor: 3.267

2.  Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989.

Authors:  A Fenoll; C Martín Bourgon; R Muñóz; D Vicioso; J Casal
Journal:  Rev Infect Dis       Date:  1991 Jan-Feb

Review 3.  The pharmacokinetics of the oral cephalosporins--a review.

Authors:  R Wise
Journal:  J Antimicrob Chemother       Date:  1990-12       Impact factor: 5.790

4.  Loracarbef concentrations in middle ear fluid.

Authors:  H Kusmiesz; S Shelton; O Brown; S Manning; J D Nelson
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

5.  Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates. Resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S aureus colonization.

Authors:  L R Peterson; J N Quick; B Jensen; S Homann; S Johnson; J Tenquist; C Shanholtzer; R A Petzel; L Sinn; D N Gerding
Journal:  Arch Intern Med       Date:  1990-10

Review 6.  Strategies to minimize the development of antibiotic resistance.

Authors:  F Baquero; M C Negri
Journal:  J Chemother       Date:  1997-05       Impact factor: 1.714

Review 7.  Pneumococcal resistance to antibiotics.

Authors:  K P Klugman
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

8.  Pharmacology of Cefuroxime as the 1-acetoxyethyl ester in volunteers.

Authors:  S M Harding; P E Williams; J Ayrton
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

9.  New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity.

Authors:  S Grasso; G Meinardi; I de Carneri; V Tamassia
Journal:  Antimicrob Agents Chemother       Date:  1978-04       Impact factor: 5.191

Review 10.  Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections.

Authors:  G L Drusano; W A Craig
Journal:  J Chemother       Date:  1997-05       Impact factor: 1.714

View more
  5 in total

Review 1.  A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints.

Authors:  A Dalhoff; P G Ambrose; J W Mouton
Journal:  Infection       Date:  2009-07-23       Impact factor: 3.553

2.  Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model.

Authors:  I Gustafsson; E Löwdin; I Odenholt; O Cars
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

Review 3.  Clinical role of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  Nelson Lee; Kwok-Yung Yuen; Cyrus R Kumana
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  Acute otitis media in children: association with day care centers--antibacterial resistance, treatment, and prevention.

Authors:  David Greenberg; Sigalit Hoffman; Eugene Leibovitz; Ron Dagan
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

5.  Bioequivalence evaluation of two capsule formulations of amoxicillin in healthy adult male bangladeshi volunteers: A single-dose, randomized, open-label, two-period crossover study.

Authors:  Ashik Ullah; Mohammad Abul Kalam Azad; Rebeka Sultana; Maruf Mohammad Akbor; Ahasanul Hasan; Mahbub Latif; Abul Hasnat
Journal:  Curr Ther Res Clin Exp       Date:  2008-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.